CCCC vs CL · rev $35.6M vs P/E 34, rev $20.38B
C4 Therapeutics Inc (CCCC) versus Colgate-Palmolive Company (CL) — a side-by-side from cached financials, not a winner call.
C4 Therapeutics Inc (CCCC) is a biotechnology company listed on US.
Colgate-Palmolive Company (CL) is a household & personal products company listed on US.
Latest reported CCCC revenue for 2024-12-31 was $35.6M. Net income was -$105.3M. Revenue was up 71.4% from 2023-12-31 to 2024-12-31. CCCC currently screens at market cap $425.7M.
Latest reported CL revenue for 2025-12-31 was $20.38B. Net income was $2.13B. Revenue was up 1.4% from 2024-12-31 to 2025-12-31. CL currently screens at market cap $70.88B and trailing P/E 34.3.
CCCC currently screens at market cap $425.7M. CL currently screens at market cap $70.88B and trailing P/E 34.3.
Not investment advice. Open the CCCC and CL stock pages for the full models.
Not investment advice.